Drug intelligence / Profile preview

autologous adipose-derived stromal cells (Ageless Regenerative Institute)

Development stage
Unknown
Lead developer
Ageless Regenerative Institute
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

This investigational cell therapy consists of autologous adipose-derived stromal cells (ADSCs) developed by the Ageless Regenerative Institute for the treatment of autism spectrum disorder (ASD). The therapy involves a multi-step process: harvesting adipose (fat) tissue from the patient via a local liposuction procedure, isolating the stromal cells from the tissue, and delivering these cells back to the same patient through intravenous injection. ADSCs are a type of mesenchymal stem cell (MSC) that possess immunomodulatory, anti-inflammatory, and potential neuroprotective properties. In patients with autism, the therapy is hypothesized to address underlying neuroinflammation and promote tissue repair through the secretion of various cytokines and growth factors. The clinical development of this therapy was focused on assessing the safety and potential behavioral improvements in children with ASD through open-label clinical trials.

Other names
adipose-derived stromal cellsADSCsautologous adipose-derived mesenchymal stem cellsadipose-derived stem cells

Beyond the preview

Go deeper on autologous adipose-derived stromal cells (Ageless Regenerative Institute).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous adipose-derived stromal cells (Ageless Regenerative Institute).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call